Merck’s 2025 guidance fell short of Wall Street expectations. - Spencer Platt/Getty Images Investors have taken to punishing pharma companies that appear unable to gauge demand for their top ...

Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.

My most recent article was written on June 10, titled “Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying.” Since then, the stock has gotten cheaper (read: it has crashed ...

Otsuka and Lundbeck’s Rxulti (marketed as Rexulti in the U.S.) , Merck’s Sivextro and Neurim Pharmaceutical’s Slenyto. As for withdrawals, Advanz Pharma in December took back (PDF ...

That R&D takes place not only at big pharma companies—household names such as Pfizer and Merck—but also at smaller, less well-known but no less heroic biosciences startups, such as Vivek ...

WEST LAFAYETTE, Ind. — Purdue University, in collaboration with Eli Lilly and Company and Merck & Co. Inc., announced Friday (Jan. 17) the launch of the Young Institute Pharmaceutical Manufacturing ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products.

Earnings are painting a mixed picture within the pharmaceutical space Tuesday morning, as Merck (MRK) and Pfizer (PFE) reported their fourth quarter results.

With a market cap of $255 billion, Merck ranks fourth amongst global pharmaceutical companies by valuation. Among the top ten largest pharmaceutical companies, the average PE is currently 19.4x.